(Q64923680)

1 July 2019

review article

1 reference

title

[Blocking adhesion molecules with natalizumab in multiple sclerosis]. (English)

1 reference

1 July 2019

author

Heinz Wiendl

5

1 reference

1 July 2019

author name string

B Schreiner

1

1 reference

1 July 2019

B C Kieseier

2

1 reference

1 July 2019

H-P Hartung

3

1 reference

1 July 2019

R Hohlfeld

4

1 reference

1 July 2019

language of work or name

German

0 references

publication date

1 August 2005

1 reference

1 July 2019

published in

Der Nervenarzt

1 reference

1 July 2019

volume

76

1 reference

1 July 2019

issue

8

1 reference

1 July 2019

page(s)

999-1005

1 reference

1 July 2019

https://scigraph.springernature.com/pub.10.1007/s00115-005-1900-2

exact match

0 references

cites work

Adhesion molecule expression and regulation on cells of the central nervous system

1 reference

12 December 2020

[Antegren (natalizumab). A promising new approach to therapy of multiple sclerosis]

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels

1 reference

12 December 2020

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

1 reference

12 December 2020

Engineering antibodies for therapy

1 reference

12 December 2020

Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.

1 reference

12 December 2020

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis

1 reference

12 December 2020

Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss

1 reference

12 December 2020

Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002

1 reference

12 December 2020

Alpha 4 beta 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

12 December 2020

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

1 reference

12 December 2020

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis

1 reference

12 December 2020

Integrins: bidirectional, allosteric signaling machines

1 reference

12 December 2020

Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE.

1 reference

12 December 2020

Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions

1 reference

12 December 2020

Natalizumab for active Crohn's disease

1 reference

12 December 2020

Natalizumab. Elan/Biogen

1 reference

12 December 2020

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

12 December 2020

Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

12 December 2020

The pathophysiologic role of alpha 4 integrins in vivo

1 reference

12 December 2020

Amyotrophic lateral sclerosis and vitamin E.

1 reference

12 December 2020

Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis

1 reference

12 December 2020

10.1007/S00115-005-1900-2

Identifiers

DOI

1 reference

1 July 2019

Dimensions Publication ID

1011146061

0 references

1 reference

1 July 2019